Eagle Pharmaceuticals Company Profile (NASDAQ:EGRX)

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) issued its quarterly earnings data on Monday, May, 8th. The company reported $1.42 earnings per share for the quarter, missing the consensus estimate of $1.44 by $0.02. The business had revenue of $76.80 million for the quarter, compared to the consensus estimate of $70.10 million. Eagle Pharmaceuticals had a net margin of 20.06% and a return on equity of 25.63%. Eagle Pharmaceuticals's revenue was up 159.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.06) EPS. View Eagle Pharmaceuticals' Earnings History.

5 analysts have issued 12-month target prices for Eagle Pharmaceuticals' stock. Their predictions range from $57.00 to $118.00. On average, they expect Eagle Pharmaceuticals' share price to reach $91.50 in the next twelve months. View Analyst Ratings for Eagle Pharmaceuticals.

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (5/10/2017)
• 2. Mizuho analysts commented, "We remain cautious on 2017 revenue, the exertional heat stroke (EHS) launch, and lower takeout probability: Eagle reported 4Q:16 revs of $81.1M and GAAP EPS of $3.52 vs. FactSet consensus $86.0M and $2.82. Mgmt introduced FY:17 SG&A guidance of $65-$68M and $31-$35M in R&D. Consensus models are in line with these expense ranges, but we think that 2017 revenue expectations (particularly Ryanodex) need to come down based on a slower EHS ramp. Because we now have a better appreciation for the hurdles associated with this launch, we also lowered our probability of takeout to 40%, from 50% previously. On a standalone basis, we think that EGRX is only worth $54/share so the stock already reflects expectations of a takeout, in our view. We reiterate our Underperform rating and $66 PT, which are based on a weighted blend of DCF ($54) and SOTP ($85) valuations." (3/17/2017)

Eagle Pharmaceuticals saw a drop in short interest during the month of April. As of April 28th, there was short interest totalling 3,366,915 shares, a drop of 2.4% from the April 13th total of 3,448,354 shares. Based on an average daily volume of 219,049 shares, the days-to-cover ratio is presently 15.4 days.

Some companies that are related to Eagle Pharmaceuticals include Pacira Pharmaceuticals (PCRX), Supernus Pharmaceuticals (SUPN), Horizon Pharma PLC (HZNP), Diplomat Pharmacy (DPLO), Momenta Pharmaceuticals (MNTA), Lannett Company (LCI), Flexion Therapeutics (FLXN), Versartis (VSAR), Karyopharm Therapeutics (KPTI), Adamas Pharmaceuticals (ADMS), Aquinox Pharmaceuticals (AQXP), Rigel Pharmaceuticals (RIGL), Tetraphase Pharmaceuticals (TTPH), Collegium Pharmaceutical (COLL), Zynerba Pharmaceuticals (ZYNE), Neos Therapeutics (NEOS), Catalyst Pharmaceuticals (CPRX) and Agile Therapeutics (AGRX).

Eagle Pharmaceuticals' management team includes the folowing people:

• Michael Graves, Independent Chairman of the Board
• David M. Pernock, President, Chief Commercial Officer
• Scott L. Tarriff, Chief Executive Officer, Independent Director
• David E. Riggs, Chief Financial Officer
• Steven L. Krill Ph.D., Executive Vice President, Chief Scientific Officer
• Adrian Hepner M.D., Executive Vice President, Chief Medical Officer
• Douglas L. Braunstein, Director
• Richard Edlin, Director
• Robert L. Glenning, Director
• Edward Kay, Director

Eagle Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include ProQuest Associates IV LLC (23.87%), Janus Capital Management LLC (9.51%), BlackRock Inc. (7.93%), Victory Capital Management Inc. (7.04%), Iridian Asset Management LLC CT (4.96%) and First Eagle Investment Management LLC (4.34%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Michael Graves, Proquest Investments Iv, LP, Proquest Management Llc, Richard A Edlin, Sander A Flaum, Sander A Flaum, Scott Tarriff, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Eagle Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including ProQuest Associates IV LLC, Park West Asset Management LLC, State Street Corp, Morgan Stanley, Janus Capital Management LLC, Ranger Investment Management L.P., UBS Group AG and PNC Financial Services Group Inc.. Company insiders that have sold Eagle Pharmaceuticals stock in the last year include Proquest Investments Iv, LP, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Insider Buying and Selling for Eagle Pharmaceuticals.

Eagle Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Iridian Asset Management LLC CT, FMR LLC, Victory Capital Management Inc., Rice Hall James & Associates LLC, Quantitative Investment Management LLC, Gotham Asset Management LLC and Capital Fund Management S.A.. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Michael Graves and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $75.01.